We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Beckman Coulter Offers Latest Innovations in Urinalysis and Automation at AACC 2021

By LabMedica International staff writers
Posted on 27 Sep 2021
Print article
Image: DxA 5000 Fit Workflow Automation System (Photo courtesy of Beckman Coulter)
Image: DxA 5000 Fit Workflow Automation System (Photo courtesy of Beckman Coulter)

Beckman Coulter, Inc. (Brea, CA, USA) displayed its latest innovations in urinalysis and automation that are designed to improve lab workflow at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo.

AACC 2021 was a live event held at the Georgia World Congress Center in Atlanta on September 26-30. At this year’s AACC Clinical Lab Expo, more than 700 exhibitors displayed the latest diagnostic technology, including but not limited to mobile health, molecular diagnostics, mass spectrometry, point-of-care, and automation. Beckman Coulter introduced its latest urinalysis solutions that continue to build upon its Iris legacy.

Beckman Coulter showcased its iRICELL series of automated walk-away workcells that delivers maximum efficiency and productivity for low- to high-volume labs. The iRICELL series combines urine chemistry and microscopy in a fully automated, walk-away workcell that is easy to use and maintain. It allows labs to optimize and advance urinalysis and body fluid testing with the company’s proprietary Digital Flow Morphology technology that uses Auto-particle Recognition (APR) software to deliver standardized and accurate results.

Beckman Coulter also highlighted its iQ200 series designed for low- to high-volume workloads, automating sample microscopy and producing shortened TAT. By leveraging its proprietary Digital Flow Morphology technology using Auto-Particle Recognition (APR) Software, urine particles are isolated, identified and characterized on the screen to virtually eliminate the need for manual microscopy. The iQ200 series analyzers are available as either stand-alone instruments or they can be connected to an iChemVELOCITY urine chemistry analyzer to form an automated iRICELL workcell.

Also on display at the event was Beckman Coulter’s iChemVELOCITY, a fully automated urine analyzer that provides results for ascorbic acid levels in samples. The iChemVELOCITY sets the standard for automated urine chemistry analysis with the development of the ascorbic acid test pad to identify possible ascorbic acid interference with key chemistry assays, ensuring laboratories receive clinically relevant information. This urine chemistry instrument offers high throughput of up to 210 samples per hour and ease of use to maximize lab performance and productivity.

Beckman Coulter also introduced the newest connection to DxA 5000 Fit, a workflow-automation solution designed to fit into medium-sized labs that run fewer than 5,000 tests a day. The DxA 5000 Fit is designed for laboratories with space constraints, yet, its scalable design allows it to easily expand to accommodate growing workloads. With the DxA 5000 Fit, mid-sized labs can enjoy the same benefits as larger-volume labs.

Related Links:
Beckman Coulter, Inc.

Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Unstirred Waterbath
HumAqua 5
New
Hemoglobin/Haptoglobin Assay
IDK Hemoglobin/Haptoglobin Complex ELISA

Print article
ADLM

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.